Natural killer cells for hard-to-treat neuroblastoma
Part of Cancer clinical trials.
This trial tests specially prepared immune cells (called CIML-NK cells) from a partially matched family donor to fight neuroblastoma that has returned or stopped responding to standard treatment. The goal is to see if these cells can help patients whose cancer is difficult to control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 1 and 39 years old
- You must have neuroblastoma that has come back or stopped responding to standard chemotherapy
- Your cancer must be classified as high-risk or have become high-risk over time
- You must have a partially matched family donor (parent, sibling, or other close relative) available
- Your heart, lungs, blood counts, and kidneys must be working well enough (specific measurements required)
- You cannot have an active, uncontrolled infection or have received a live vaccine in the past month
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new natural killer (NK) cell therapy from donated umbilical cord blood for children with high-risk neuroblastoma that has come back or not responded to treatment. The goal is to see if this immune cell therapy is safe and can help fight the cancer.
This trial tests a new treatment combining your child's own immune cells (NK cells) with an antibody that targets neuroblastoma cells. It is for children who have just finished standard treatment or whose cancer has come back or not responded, and aims to improve outcomes.
This trial tests a modified version of your own immune cells (made from your blood) to help treat advanced cancers that are no longer responding to standard treatment. It’s designed mainly to see if the approach is safe and how well it may work for people whose disease has progressed.
This trial tests combining two immune-boosting drugs (naxitamab and GM-CSF) with a vitamin-A derivative (isotretinoin) to keep high-risk neuroblastoma in remission after standard treatment. It aims to see if this maintenance treatment helps prevent the cancer from returning.
This Phase 1 study tests lab-made donor immune cells (gamma delta T cells) plus chemotherapy to treat neuroblastoma or osteosarcoma that has come back or hasn’t responded to standard treatment. It’s designed to find a safe way to give this treatment and to see how well it might work.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.